Selected research
Industry Research
Nonalcoholic Steatohepatitis Treatment Industry Research Report 2026
Market perspective
The global Nonalcoholic Steatohepatitis Treatment market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Nonalcoholic Steatohepatitis Treatment market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Nonalcoholic Steatohepatitis Treatment market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Nonalcoholic Steatohepatitis Treatment market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Nonalcoholic Steatohepatitis Treatment include Arena Pharmaceuticals, Arisaph Pharmaceuticals, Cempra Pharmaceuticals, Galectin Therapeutics, Galmed Pharmaceuticals, Genfit, Gilead, Novo Nordisk and Vivus, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Nonalcoholic Steatohepatitis Treatment market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Nonalcoholic Steatohepatitis Treatment.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Nonalcoholic Steatohepatitis Treatment Market by Company
Arena Pharmaceuticals
Arisaph Pharmaceuticals
Cempra Pharmaceuticals
Galectin Therapeutics
Galmed Pharmaceuticals
Genfit
Gilead
Novo Nordisk
Vivus
AstraZeneca
GSK
Roche
Nonalcoholic Steatohepatitis Treatment Segment by Type
Solid
Liquid
Nonalcoholic Steatohepatitis Treatment Segment by Application
Drug Store
Hospital
Hospital Pharmacy
Mail Order Pharmacy
Diagnostic Center
Specialized Clinic
Nonalcoholic Steatohepatitis Treatment Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Nonalcoholic Steatohepatitis Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Nonalcoholic Steatohepatitis Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Nonalcoholic Steatohepatitis Treatment.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Nonalcoholic Steatohepatitis Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Solid
- Liquid
Applications
- Drug Store
- Hospital
- Hospital Pharmacy
- Mail Order Pharmacy
- Diagnostic Center
- Specialized Clinic
Companies covered
- Arena Pharmaceuticals
- Arisaph Pharmaceuticals
- Cempra Pharmaceuticals
- Galectin Therapeutics
- Galmed Pharmaceuticals
- Genfit
- Gilead
- Novo Nordisk
- Vivus
- AstraZeneca
- GSK
- Roche
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Nonalcoholic Steatohepatitis Treatment by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Solid
- 2.2.3 Liquid
- 2.3 Nonalcoholic Steatohepatitis Treatment by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Drug Store
- 2.3.3 Hospital
- 2.3.4 Hospital Pharmacy
- 2.3.5 Mail Order Pharmacy
- 2.3.6 Diagnostic Center
- 2.3.7 Specialized Clinic
- 2.4 Assumptions and Limitations
3 Nonalcoholic Steatohepatitis Treatment Breakdown Data by Type
- 3.1 Global Nonalcoholic Steatohepatitis Treatment Historic Market Size by Type (2021-2026)
- 3.2 Global Nonalcoholic Steatohepatitis Treatment Forecasted Market Size by Type (2027-2032)
4 Nonalcoholic Steatohepatitis Treatment Breakdown Data by Application
- 4.1 Global Nonalcoholic Steatohepatitis Treatment Historic Market Size by Application (2021-2026)
- 4.2 Global Nonalcoholic Steatohepatitis Treatment Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Nonalcoholic Steatohepatitis Treatment Market Perspective (2021-2032)
- 5.2 Global Nonalcoholic Steatohepatitis Treatment Growth Trends by Region
- 5.2.1 Global Nonalcoholic Steatohepatitis Treatment Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Nonalcoholic Steatohepatitis Treatment Historic Market Size by Region (2021-2026)
- 5.2.3 Nonalcoholic Steatohepatitis Treatment Forecasted Market Size by Region (2027-2032)
- 5.3 Nonalcoholic Steatohepatitis Treatment Market Dynamics
- 5.3.1 Nonalcoholic Steatohepatitis Treatment Industry Trends
- 5.3.2 Nonalcoholic Steatohepatitis Treatment Market Drivers
- 5.3.3 Nonalcoholic Steatohepatitis Treatment Market Challenges
- 5.3.4 Nonalcoholic Steatohepatitis Treatment Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Nonalcoholic Steatohepatitis Treatment Players by Revenue
- 6.1.1 Global Top Nonalcoholic Steatohepatitis Treatment Players by Revenue (2021-2026)
- 6.1.2 Global Nonalcoholic Steatohepatitis Treatment Revenue Market Share by Players (2021-2026)
- 6.2 Global Nonalcoholic Steatohepatitis Treatment Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Nonalcoholic Steatohepatitis Treatment Head Office and Area Served
- 6.4 Global Nonalcoholic Steatohepatitis Treatment Players, Product Type & Application
- 6.5 Global Nonalcoholic Steatohepatitis Treatment Manufacturers Established Date
- 6.6 Global Nonalcoholic Steatohepatitis Treatment Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Nonalcoholic Steatohepatitis Treatment Market Size (2021-2032)
- 7.2 North America Nonalcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Nonalcoholic Steatohepatitis Treatment Market Size by Country (2021-2026)
- 7.4 North America Nonalcoholic Steatohepatitis Treatment Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Nonalcoholic Steatohepatitis Treatment Market Size (2021-2032)
- 8.2 Europe Nonalcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Nonalcoholic Steatohepatitis Treatment Market Size by Country (2021-2026)
- 8.4 Europe Nonalcoholic Steatohepatitis Treatment Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Nonalcoholic Steatohepatitis Treatment Market Size (2021-2032)
- 9.2 Asia-Pacific Nonalcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Nonalcoholic Steatohepatitis Treatment Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Nonalcoholic Steatohepatitis Treatment Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Nonalcoholic Steatohepatitis Treatment Market Size (2021-2032)
- 10.2 South America Nonalcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Nonalcoholic Steatohepatitis Treatment Market Size by Country (2021-2026)
- 10.4 South America Nonalcoholic Steatohepatitis Treatment Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Market Size (2021-2032)
- 11.2 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Nonalcoholic Steatohepatitis Treatment Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Arena Pharmaceuticals
- 12.1.1 Arena Pharmaceuticals Company Information
- 12.1.2 Arena Pharmaceuticals Business Overview
- 12.1.3 Arena Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.1.4 Arena Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.1.5 Arena Pharmaceuticals Recent Developments
- 12.2 Arisaph Pharmaceuticals
- 12.2.1 Arisaph Pharmaceuticals Company Information
- 12.2.2 Arisaph Pharmaceuticals Business Overview
- 12.2.3 Arisaph Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.2.4 Arisaph Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.2.5 Arisaph Pharmaceuticals Recent Developments
- 12.3 Cempra Pharmaceuticals
- 12.3.1 Cempra Pharmaceuticals Company Information
- 12.3.2 Cempra Pharmaceuticals Business Overview
- 12.3.3 Cempra Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.3.4 Cempra Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.3.5 Cempra Pharmaceuticals Recent Developments
- 12.4 Galectin Therapeutics
- 12.4.1 Galectin Therapeutics Company Information
- 12.4.2 Galectin Therapeutics Business Overview
- 12.4.3 Galectin Therapeutics Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.4.4 Galectin Therapeutics Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.4.5 Galectin Therapeutics Recent Developments
- 12.5 Galmed Pharmaceuticals
- 12.5.1 Galmed Pharmaceuticals Company Information
- 12.5.2 Galmed Pharmaceuticals Business Overview
- 12.5.3 Galmed Pharmaceuticals Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.5.4 Galmed Pharmaceuticals Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.5.5 Galmed Pharmaceuticals Recent Developments
- 12.6 Genfit
- 12.6.1 Genfit Company Information
- 12.6.2 Genfit Business Overview
- 12.6.3 Genfit Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.6.4 Genfit Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.6.5 Genfit Recent Developments
- 12.7 Gilead
- 12.7.1 Gilead Company Information
- 12.7.2 Gilead Business Overview
- 12.7.3 Gilead Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.7.4 Gilead Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.7.5 Gilead Recent Developments
- 12.8 Novo Nordisk
- 12.8.1 Novo Nordisk Company Information
- 12.8.2 Novo Nordisk Business Overview
- 12.8.3 Novo Nordisk Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.8.4 Novo Nordisk Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.8.5 Novo Nordisk Recent Developments
- 12.9 Vivus
- 12.9.1 Vivus Company Information
- 12.9.2 Vivus Business Overview
- 12.9.3 Vivus Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.9.4 Vivus Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.9.5 Vivus Recent Developments
- 12.10 AstraZeneca
- 12.10.1 AstraZeneca Company Information
- 12.10.2 AstraZeneca Business Overview
- 12.10.3 AstraZeneca Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.10.4 AstraZeneca Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.10.5 AstraZeneca Recent Developments
- 12.11 GSK
- 12.11.1 GSK Company Information
- 12.11.2 GSK Business Overview
- 12.11.3 GSK Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.11.4 GSK Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.11.5 GSK Recent Developments
- 12.12 Roche
- 12.12.1 Roche Company Information
- 12.12.2 Roche Business Overview
- 12.12.3 Roche Revenue in Nonalcoholic Steatohepatitis Treatment Business (2021-2026)
- 12.12.4 Roche Nonalcoholic Steatohepatitis Treatment Product Portfolio
- 12.12.5 Roche Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst